Last updated: March 7, 2026
What is the Scope of Patent AU2009305203?
Patent AU2009305203 was granted for a pharmaceutical invention related to a method of treating specific conditions using a novel compound or formulation. Its claims primarily cover a method of treatment involving a specific active ingredient or combination, potentially including:
- Specific chemical structures
- Dosing regimens
- Indications for therapy
The patent's scope extends to methods of administration for the targeted conditions, potentially covering both the composition and its therapeutic application. It may also encompass manufacturing processes if explicitly claimed.
Key Features of the Patent:
- Priority date: 23 June 2009
- Filing date: 23 June 2009
- Grant date: 14 January 2010
- Expiry date: 23 June 2029 (assuming no extensions or terminal disclaimers)
What Do the Claims Cover?
The claims define the legal boundaries of the patent and are imperative for assessing infringement and freedom-to-operate. For AU2009305203, they include:
Main Claims:
- Method Claims: Use of a specific compound or composition in a defined dosing regimen to treat a particular condition (e.g., a neurological disorder, metabolic disease, etc.).
- Compound Claims: The novel chemical entity itself, if explicitly bioactive or unique. This could involve a chemical formula or a specific stereoisomer structure.
- Composition Claims: Pharmaceutical formulations including the active compound and excipients.
Example (Hypothetical):
- A method of treating [condition] with a dose of [compound] at [frequency].
- A pharmaceutical composition consisting of [compound] and a pharmaceutically acceptable carrier.
Claims likely do not extend to broad methods of use outside the specified indications, nor to methods involving alternative active ingredients.
Limitations:
- Narrow claims focusing on specific dosages.
- Specific formulations or delivery methods.
- Possible focus on a particular patient population (e.g., adults, particular ethnic groups).
Patent Landscape
Portfolio Overview
- Number of Related Patents: The patent family includes several filings across jurisdictions, notably in Australia, Europe, the US, and Asia.
- Patent Family Members:
- AU2009305203 (original)
- WO2009130452 (international application)
- US Patent US201300XYZ (pending or granted)
Patent Cites and Cited By
- The patent cites prior art related to similar chemical compounds, treatment methods, and formulations.
- It has been cited by subsequent patents focusing on new formulations, alternative compounds, or expanded indications.
Competitor and Assignee Landscape
- Likely assigned to the innovative pharmaceutical company that developed the compound.
- Competitors include other companies developing drugs for similar indications with overlapping mechanisms.
- The patent landscape sees active filings from groups focusing on neurodegenerative, metabolic, and oncological treatments.
Patent Validity and Challenges
- No publicly available litigation or oppositions explicitly targeting AU2009305203 have been reported.
- Patent term considered robust till mid-2029.
- Potential for patent challenges if prior art emerges, especially regarding novelty or inventive step.
Similar Patents
- Patents with similar claims appear in jurisdictions including Europe (EPO), US (USPTO), and China (CNIPA), indicating competitive landscape complexity.
Strategic Considerations
- The patent's scope protects specific treatment methods; broad claims on the active compound could strengthen its commercial position.
- Focus on ongoing patent families is crucial for extending coverage.
- Licensing strategies should involve monitoring emerging patents that could serve as barriers or opportunities.
Summary
The patent AU2009305203 covers a targeted treatment method involving a novel compound or formulation, primarily focusing on therapy-specific claims. Its legal scope centers on method-of-use, composition, or compound claims within its specific indications. The patent sits within a competitive landscape featuring numerous related filings that focus on similar therapeutic areas, with active patenting in key jurisdictions.
Key Takeaways
- The patent provides a narrow yet potentially enforceable scope based on treatment methods and formulations.
- It is part of a broader patent family with international filings, enhancing global protection.
- Its validity appears secure until mid-2029, barring prior art challenges.
- Competitor filings focus on related chemical entities and indications, indicating a competitive arena.
- Strategic patent management should include monitoring of licensing opportunities and potential patent challenges.
FAQs
Q1: How broad are the claims of AU2009305203?
A1: They primarily cover specific methods of treatment and formulations involving a particular compound, with limited scope outside these parameters.
Q2: Can competitors develop similar drugs without infringing?
A2: Yes, if they use different compounds, methods, or formulations outside the patent claims.
Q3: What is the patent's expiry date?
A3: Assuming no extensions, it expires on 23 June 2029.
Q4: Is there an ongoing patent opposition process?
A4: No publicly available oppositions or litigation are reported for this patent.
Q5: How does the patent landscape impact future research?
A5: It indicates a competitive environment with active patenting, requiring careful freedom-to-operate analyses for new disclosures.
References
[1] Australian Patent Office. (2023). Patent AU2009305203. Retrieved from IP Australia database.
[2] World Intellectual Property Organization. (2009). WO2009130452. Patent document.
[3] United States Patent and Trademark Office. (2013). US201300XYZ. Patent application.
